Active Biotech and Teva Initiate Pivotal Phase III Trial of Laquinimod
Active Biotech AB and Teva Pharmaceutical Industries Ltd. have announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis, RMS. The studies will begin following the successful conclusion of a second Phase II study and the outcome of discussions with the U.S. Food and Drug Administration and the European Medicines Agency.
The companies are to commence two global Phase III trials of laquinimod. The Phase III trials will take place in centres in the United States, Europe, and other locations worldwide, to further confirm the results of the Phase II trials. The trials showed that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging, MRI, disease activity by 40 percent in RMS patients and was well tolerated.
For further information please contact:
Sven Andréasson,
President & CEO
Tel: +46 46 19 20 49
Email: sven.andreasson@activebiotech.com
Or visit: www.activebiotech.com
Active Biotech is a publicly traded Swedish biotechnology company. The company has five projects in clinical development for the treatment of serious autoimmune/inflammatory diseases and cancer. Laquinimod - a novel oral treatment of multiple sclerosis – is developed through a cooperation with Teva ...